RLAY at a glance
Relay Therapeutics, Inc. (RLAY, SEC CIK 1812364) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Relay Therapeutics, Inc. (RLAY) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Patel Sanjiv on November 19, 2026 of 48,202 shares at $16.13 per share.
- In the last 90 days, RLAY insiders reported 0 open-market purchases ($0) and 14 open-market sales ($120.7M) on Form 4, a net sale of $120.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $15.4M
- +53.4% vs prior year
- Insiders · 90 days
- 0 buys · 14 sells
- Net −$120.7M
- 13F holders
- 28 funds
- $1.2B · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development
- Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals
- Dependence on third-party CROs and diagnostic partners, which may fail to meet contractual or regulatory requirements, delaying trials and companion diagnostics approval
- Competition for patient enrollment from other oncology trials, including Pfizer’s selective-CDK4 inhibitor in metastatic breast cancer combination study
- High operational risk from novel mechanism drug candidates requiring extensive R&D and potential unknown adverse effects raising development costs and regulatory hurdles
Management Discussion & Analysis
- Revenue $15.4M in 2025, up $5.3M YoY from $10.0M in 2024, primarily from Elevar Agreement milestones
- Net loss $276.5M in 2025 vs $337.7M in 2024; operating expenses down to $318.1M from $382.5M; R&D $261.4M vs $319.1M, G&A $56.7M vs $76.6M
- Best performing segment: License revenue from Elevar Agreement $15.4M in 2025; worst: Research & Development with $261.4M expense in 2025
- Cash, cash equivalents, investments $554.5M as of Dec 31, 2025; raised $218.2M net in Sept 2024 offering; no share sales under $250M ATM facility; no disclosed dividends or buybacks
- Management expects significant continued operating losses; cash runway into 2029; key risks include clinical trial progress, capital raising, regulatory approvals, and geopolitical/economic uncertainties
AI summary of the RLAY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: BIOSECURE Act enacted December 18, 2025, potentially restricting WuXi AppTec arrangements from 2027 or later
- Most material operational update: WuXi AppTec’s 1260H designation litigation, preliminary injunction granted August 7, 2026
- Clinical risk: FDA may require a companion diagnostic for zovegalisib in biomarker-defined populations
- Financial risk: $238.7 million net loss and $2.3 billion accumulated deficit as of September 30, 2026
- Funding risk: $463.0 million remaining at-the-market common-stock capacity, subject to dilution risk
Management Discussion & Analysis
- Quarterly revenue $0 vs $0 YoY, with no product sales
- Net loss $81.7M vs $74.1M YoY, operating loss $90.2M vs $80.4M
- R&D expense $77.1M vs $68.3M, clinical-trial costs $45.2M vs $34.0M
- Cash, equivalents and investments $848.6M, operating cash outflow $169.2M through nine months
- May offering generated $296.8M net; cash expected to fund operations into 2029, with continued financing needs ahead
AI summary of the RLAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $0, net loss $81.7M, or $0.37 per share, reflecting continued clinical-stage cash burn
- Cash, equivalents and investments $848.6M, up from $554.5M at year-end, with funding expected into 2029
Item 1.01: Entry into a Material Definitive Agreement
- ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales
- Approximately $162.98M already sold under the agreement, indicating substantial prior equity financing
Item EX-99.1: Item EX-99.1
- ATM equity-sales authorization increased from $250 million to $462,978,049, expanding potential financing capacity
- Additional share issuance creates dilution risk for existing shareholders and possible financing for operations or pipeline development
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.2
Item EX-99.2: Item EX-99.2
- Q2 revenue $0.4M, R&D $76.5M, and net loss $83.7M, reflecting accelerating clinical investment
- Cash, equivalents and investments $910.9M after $316M gross follow-on proceeds, supporting operations into 2029
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Authorized common shares increased from 300 million to 450 million
- Stockholder approval received at the 2026 Annual Meeting
Item 5.07: Submission of Matters to a Vote of Security Holders
- Class III directors Douglas S. Ingram and Claire Mazumdar re-elected through 2029
- Executive compensation approved advisory basis, 143,849,919 votes for
AI summaries of RLAY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RLAY
Don't miss the next RLAY filing
- Alerts as it files. A push when RLAY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RLAY, by share count.
- Ask anything. An AI agent that reads every RLAY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Patel Sanjiv | Sell | Nov 19, 2026 | 48,202 | $16.13 |
| Catinazzo Thomas | Sell | Nov 18, 2026 | 32,717 | $16.51 |
| Bergstrom Donald A | Sell | Nov 18, 2026 | 10,269 | $16.51 |
| Catinazzo Thomas | Sell | Oct 28, 2026 | 1,469 | $18.62 |
| Bergstrom Donald A | Sell | Oct 28, 2026 | 2,252 | $18.62 |
| Rahmer Peter | Sell | Oct 28, 2026 | 753 | $18.62 |
| Patel Sanjiv | Sell | Oct 7, 2026 | 48,199 | $18.10 |
| Catinazzo Thomas | Sell | Oct 6, 2026 | 206 | $19.26 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $25.5M | $10.0M | $15.4M |
| Operating Income | - | -$372.5M | -$302.7M |
| Net Income | -$342.0M | -$337.7M | -$276.5M |
| Op. Margin | - | -3722.1% | -1971.6% |
| Net Margin | -1338.7% | -3374.7% | -1800.6% |
| Balance Sheet | |||
| Total Assets | - | $871.3M | $621.3M |
| Equity | - | $777.8M | $567.1M |
| ROE | - | -43.4% | -48.8% |
| Per Share | |||
| EPS | $-2.79 | $-2.36 | $-1.61 |
| Cash Flow | |||
| Operating CF | - | -$249.1M | -$235.5M |
| CapEx | $4.1M | $2.0M | $410K |
Source: XBRL data in Relay Therapeutics, Inc. (RLAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RLAY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $1.20B |
| Q2 2026 | 30 | $1.69B |
| Q1 2026 | 29 | $523.5M |
| Q4 2025 | 24 | $404.4M |
| Q3 2025 | 27 | $241.1M |
| Q2 2025 | 28 | $186.4M |
| Q1 2025 | 26 | $106.3M |
| Q4 2024 | 22 | $139.2M |
- BlackRock+1.41M (+9%)
- Two Sigma Investments+1.06M (+151%)
- Bank of America Corp+408.3K (+15%)
- Invesco Ltd+196.4K (+28%)
- Franklin Resources+122.4K (+7%)
- Morgan Stanley−1.26M (-33%)
- Goldman Sachs Group−1.12M (-33%)
- T. Rowe Price Group−1.08M (-14%)
- State Street Corp−974.2K (-10%)
- Millennium Management−577.5K (-98%)
- FMR LLC (Fidelity)−20.11M
- Renaissance Technologies LLC−192.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RLAY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RLAY SEC filings: frequently asked questions
Are RLAY insiders buying or selling?
In the last 90 days, Relay Therapeutics, Inc. (RLAY) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $120.7 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RLAY stock?
As of September 30, 2026, the largest Relay Therapeutics, Inc. (RLAY) holders among the 13F filers tracked by SignalX were BlackRock ($301.4 million), State Street Corp ($165.2 million), Vanguard Capital Management LLC ($162.7 million), T. Rowe Price Group ($119.7 million), Dimensional Fund Advisors ($57.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RLAY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Relay Therapeutics, Inc. (RLAY) reported revenue of $15.4 million (up 53.4% from FY2024) and a net loss of $276.5 million. Diluted EPS was -$1.61. The figures come from the XBRL data in the 10-K.
What are the main risks in RLAY's latest 10-K?
In the 10-K filed February 26, 2026, Relay Therapeutics, Inc. (RLAY) flagged: FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development. Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals. (AI summary of the Risk Factors section.)
What did RLAY report in its latest 8-K?
Relay Therapeutics, Inc. (RLAY) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest RLAY SEC filings?
Relay Therapeutics, Inc. (RLAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 20, 2026.
What is RLAY's SEC CIK number?
Relay Therapeutics, Inc. (RLAY)'s SEC Central Index Key (CIK) is 1812364. EDGAR lists every RLAY filing under that number.
Ask anything about RLAY
The research agent reads RLAY's filings, financials, insider trades and 13F holders, then answers with sources.